Antiangiogenic agents in natural products for the treatment of gynecologic disorders

Nutrition and Cancer

Volumn 66, Issue 2, 2014, Pages 206-213

  Aghamohammadi, Azar ^a,b   Hosseinimehr, Seyed Jalal ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHOCYANIN; APIGENIN; ARTEMISININ; BAICALEIN; BAICALIN; BERBERINE; CAMPESTEROL; CURCUMIN; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; ERGOSTEROL; GALLIC ACID; GENISTEIN; GINKGOLIDE B; GUGGULSTERONE; HONOKIOL; KRESTIN; NATURAL PRODUCT; OCTACOSANOL; RESVERATROL; SILYMARIN; SQUALAMINE; THYMOQUINONE; VISCUM ALBUM LECTIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; ENDOMETRIOSIS; GYNECOLOGIC CANCER; GYNECOLOGIC DISEASE; HUMAN; NONHUMAN; UTERUS MYOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; FEMALE; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84895099026     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.865136     Document Type: Article

References (99)

1. Gerger A, LaBonte M, and Lenz HJ: Molecular predictors of response to antiangiogenesis therapies. The Cancer Journal 17, 134, 2011.
2. Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, et al.: Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 20, 225-234, 2009.
3. Hayrabedyan S, Kyurkchiev S, and Kehayov I: FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis. Journal of Reproductive Immunology 67(1-2), 87-101, 2005. (Pubitemid 41415559)
4. Jeong SJ, Koh W, Lee EO, Lee HJ, Bae H, Lü J, et al.: Antiangiogenic phytochemicals and medicinal herbs. Phytotherapy Research 25, 1-10, 2011.
5. Augustin HG: Antiangiogenic tumour therapy: will it work? Trends in Pharmacological Sciences 19, 216-222, 1998. (Pubitemid 28312166)
6. Sagar SM, Yance D, and Wong R: Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Current Oncology 13, 14, 2006.
7. Sherwood LM, Parris EE, and Folkman J: Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285, 1182-1186, 1971.
8. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1, 27-30, 1995.
9. Becker CM and D'Amato RJ: Angiogenesis and antiangiogenic therapy in endometriosis. Microvascular Research 74, 121-130, 2007. (Pubitemid 350051024)
10. Wang S, Zheng Z, Weng Y, Yu Y, Zhang D, et al.: Angiogenesis and antiangiogenesis activity of Chinese medicinal herbal extracts. Life Sciences 74, 2467-2478, 2004. (Pubitemid 38324603)
11. Verheul HMW and Pinedo HM: Possiblemolecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer 7, 475-485, 2007. (Pubitemid 46809172)
12. Gotink KJ and Verheul HMW: Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13, 1-14, 2010.
13. Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 8, 592-603, 2008.
14. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, and Harrington K: Bevacizumab-induced hypertension: pathogenesis and management. Bio-Drugs 25, 159-169, 2011.
15. Abulafia O and Sherer DM: Angiogenesis of the endometrium. Obstetrics & Gynecology 94, 148, 1999.
16. Xu H, Becker CM, Lui WT, Chu CY, Davis TN, et al.: Green tea epigallocatchin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis inávivo. Fertility and Sterility 96, 1021-1028, 2011.
17. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V, et al.: Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertility and Sterility 94, 1887-1893, 2010.
18. PapettiMand Herman IM: Mechanisms of normal and tumor-derived angiogenesis. American Journal of Physiology-Cell Physiology 282, C947-C70, 2002.
19. Zhou X, Li Y, and Chen X:Computational identification of bioactive natural products by structure activity relationship. Journal of Molecular Graphics and Modelling 29, 38-45, 2010.
20. Singh SB and Barrett JF: Empirical antibacterial drug discovery-foundation in natural products. Biochemical Pharmacology 71, 1006-1015, 2006.
21. Folmer F, Jaspars M, Dicato M, and Diederich M: Marine natural products as targeted modulators of the transcription factor NF-κB. Biochemical Pharmacology 75, 603-617, 2008.
22. Wu H, Huang C, and Chang D: Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol 4, 37-45, 2008. (Pubitemid 351902823)
23. Kim MK, Kim K, Han JY, Lim JM, and Song YS: Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes & Nutrition 6, 109-115, 2011.
24. Lee H, Lee J, Gourley L, Duffy S, Day N, et al.: Dietary effects on breastcancer risk in Singapore. The Lancet 337, 1197-1200, 1991.
25. Nagai A, Yokoyama N, Matsuo T, Bork S, Hirata H, et al.: Growthinhibitory effects of artesunate, pyrimethamine, and pamaquine against Babesia equi and Babesia caballi in in vitro cultures. Antimicrob Agents Chemother 47, 800-803, 2003. (Pubitemid 36158119)
26. Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, et al.: Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. European Journal of Cancer 39, 2403-2410, 2003. (Pubitemid 37214866)
27. Li D, Williams JI, and Pietras RJ: Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 21, 2805-2814, 2002. (Pubitemid 34499377)
28. Cao Y and Cao R: Angiogenesis inhibited by drinking tea. Nature; 398, 381, 1999.
29. DeFeudis FV, Papadopoulos V, and Drieu K: Ginkgo biloba extracts and cancer: a research area in its infancy. Fundamental & Clinical Pharmacology 17, 405-417, 2003. (Pubitemid 36920641)
30. Xiao X, Shi D, Liu L, Wang J, Xie X, et al.: Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PloS One 6(8), e22934, 2011.
31. Barber R, Delahunt B, Grebe SKG, Davis PF, Thornton A, et al.: Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. Anticancer Research 21(2A), 1065-1069, 2001.
32. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, et al.: Evaluation of shark cartilage in patients with advanced cancer. Cancer 104, 176-182, 2005.
33. Halder SK, Sharan C, and Al-Hendy A: 1, 25-Dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biology of Reproduction 86, 1-10, 2012.
34. Hague S, Zhang L, Oehler MK, Manek S, MacKenzie IZ, et al.: Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clinical Cancer Research 6, 2808-2814, 2000. (Pubitemid 30482121)
35. Tsuiji K, Takeda T, Li B, Wakabayashi A, Kondo A, et al.: Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecological Endocrinology 27, 512-517, 2011.
36. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Sharan C, et al.: Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. American Journal of Obstetrics and Gynecology 202, 289.e1-289.e9, 2010.
37. Ejaz A, Wu D, Kwan P, and Meydani M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. The Journal of Nutrition 139, 919-925, 2009.
38. Mantell D, Owens P, Bundred N, Mawer E, and Canfield A: 1α, 25- dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circulation Research 87, 214-220, 2000. (Pubitemid 30626429)
39. Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, et al.: An overview on anticancer activities of the Viscum album extract Isorel®. Cancer Biotherapy and Radiopharmaceuticals 16, 55-62, 2001. (Pubitemid 32231717)
40. Nap AW, Griffioen AW, Dunselman GAJ, Bouma-Ter Steege JCA, Thijssen VLJL, et al.: Antiangiogenesis therapy for endometriosis. Journal of Clinical Endocrinology & Metabolism 89, 1089-1095, 2004. (Pubitemid 38368395)
41. Xu H, Lui W, Chu CY, Ng P, Wang CC, et al.: Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Human Reproduction 24, 608-618, 2009.
42. Zhou J and Qu F: Treating gynaecological disorderswith traditional Chinese medicine: a review. African Journal of Traditional, Complementary, and Alternative Medicines 6, 494, 2009.
43. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, et al.: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. Journal of Clinical Oncology 25, 4536-4541, 2007. (Pubitemid 350035309)
44. Martins SF, Reis RM, Rodrigues AM, Baltazar F, and Longatto Filho A: Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World Journal of Clinical Oncology 2, 272, 2011.
45. Zou L, Lai H, Zhou Q, and Xiao F: Lasting controversy on ranibizumab and bevacizumab. Theranostics 1, 395, 2011.
46. Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, et al.: Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 26, 1475-1481, 2012.
47. Mujtaba T and Dou Q: Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery Medicine 12, 471, 2011.
48. Weber D, Rankin K, Gavino M, Delasalle K, and Alexanian R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology 21, 16-19, 2003.
49. Szekanecz Z, Besenyei T, Paragh G, and Koch AE: Newinsights in synovial angiogenesis. Joint Bone Spine 77, 13-19, 2010.
50. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, et al.: Erlotinib in lung cancer-molecular and clinical predictors of outcome. New England Journal of Medicine 353, 133-144, 2005. (Pubitemid 41058345)
51. Arnold JJ and Heriot W: Age related macular degeneration. Clinical Evidence, pii: 0701 online, 2007.
52. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, and Guyer DR: Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 351, 2805-2816, 2004. (Pubitemid 40051904)
53. Doggrell SA: Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opinion on Pharmacotherapy 6, 1421-1423, 2005. (Pubitemid 41030899)
54. Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Experimental Cell Research 312, 594-607, 2006. (Pubitemid 43290336)
55. Mancuso A, Di Paola ED, Leone A, Catalano A, Calabr̀o F, et al.: Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. BJU International 109, 200-206, 2012.
56. João C, Figueiredo A, and Martins HF. Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. Current Opinion in Oncology 24, S13, 2012.
57. Yildiz I, Sen F, Basaran M, Ekenel M, Agaoglu F, et al.: Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey. Japanese Journal of Clinical Oncology 41, 1380-1387, 2011.
58. Bishayee A: Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prevention Research 2, 409-418, 2009.
59. Choi JM, Lee EO, Lee HJ, Kim KH, Ahn KS, et al.: Identification of campesterol from Chrysanthemum coronarium L. and its antiangiogenic activities. Phytotherapy Research 21, 954-959, 2007.
60. Hillman GG and Singh-Gupta V: Soy isoflavones sensitize cancer cells to radiotherapy. Free Radical Biology and Medicine 51, 289-298, 2011.
61. Wang B, Zou Y, Li H, Yan H, Pan JS, et al. Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1α in a mouse model of oxygen-induced retinopathy. Journal of Ocular Pharmacology & Therapeutics 21, 107-113, 2005. (Pubitemid 40577965)
62. Jeon KS, Na HJ, Kim YM, and Kwon HJ: Antiangiogenic activity of 4-O-methylgallic acid from Canavalia gladiata, a dietary legume. Biochemical and Biophysical Research Communications 330, 1268-1274, 2005.
63. Liu Z, Schwimer J, Liu D, Greenway FL, Anthony CT, et al.: Black raspberry extract and fractions contain angiogenesis inhibitors. Journal of Agricultural and Food Chemistry 53, 3909-3915, 2005. (Pubitemid 40936742)
64. Xu Z, Chen X, Zhong Z, Chen L, and Wang Y:Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. American Journal of Chinese Medicine 39, 15, 2011.
65. Kobayashi H, Matsunaga K, and Oguchi Y: Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiology Biomarkers & Prevention 4, 275-281, 1995.
66. Song KS, Li G, Kim JS, Jing K, Kim TD, et al.: Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cells. BMC Cancer 11, 307, 2011.
67. Sliva D, Jedinak A, Kawasaki J, Harvey K, and Slivova V: Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling. British Journal of Cancer 98, 1348-1356, 2008. (Pubitemid 351543583)
68. Pisters KMW, Newman RA, Coldman B, Shin DM, Khuri FR, et al.: Phase I trial of oral green tea extract in adult patients with solid tumors. Journal of Clinical Oncology 19, 1830-1838, 2001. (Pubitemid 32230886)
69. Zikri NN, Riedl KM, Wang LS, Lechner J, Schwartz SJ, et al.: Black raspberry components inhibit proliferation, induce apoptosis, and modulate gene expression in rat esophageal epithelial cells. Nutrition and Cancer 61, 816-826, 2009.
70. Meade-Tollin LC, Wijeratne EMK, Cooper D, Guild M, Jon E, et al.: Ponicidin and Oridonin are responsible for the antiangiogenic activity of rabdosia rubescens, a constituent of the herbal supplement PC SPES. Journal of Natural Products 67, 2-4, 2004. (Pubitemid 38141300)
71. Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, et al.: Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 26, 821-826, 2005. (Pubitemid 41214345)
72. Huh JE, Lee EO, Kim MS, Kang KS, Kim CH, et al.: Penta-O-galloylbeta-D- glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis 26, 1436-1445.
73. Lee SJ, Lee HM, Ji ST, Lee SR, Mar W, et al.: 1, 2, 3, 4, 6-Penta-O-galloylbeta-d-glucose blocks endothelial cell growth and tube formation through inhibition of VEGF binding to VEGF receptor. Cancer Letters 208, 89-94, 2004. (Pubitemid 38501788)
74. Joussen AM, Rohrschneider K, Reichling J, Kirchhof B, and Kruse FE: Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids. Experimental Eye Research 71, 483-487, 2000.
75. Izuta H, Chikaraishi Y, Shimazawa M, Mishima S, and Hara H: 10-hydroxy- 2-decenoic acid, a major fatty acid from royal jelly, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells. Evid Based Complement Alternat Med 6, 489-494, 2009.
76. Simard B, Bouamrani A, Jourdes P, Pernod G, Dimitriadou V, et al.: Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma. Microvascular Research 82, 6-17, 2011.
77. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, et al.: Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NFkB activation. FEBS Letters 552, 141-144, 2003. (Pubitemid 37186850)
78. Park WB, Lyu SY, Kim JH, Choi SH, Chung HK, et al.: Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biotherapy and Radiopharmaceuticals 16, 439-447, 2001.
79. Grossarth-Maticek R, Kiene H, Baumgartner S, and Ziegler R: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Alternative Therapies in Health and Medicine 7, 57, 2001.
80. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with highrisk or pre-malignant lesions. Anticancer Research 21, 2895, 2001.
81. Miocinovic R, McCabe NP, Keck RW, Jankun J, Hampton JA, et al.: In vivo and in vitro effect of baicalein on human prostate cancer cells. International Journal of Oncology 26, 241-246, 2005.
82. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, et al.: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. Journal of Clinical Oncology 18, 3595-3603, 2000.
83. Wen W, Lu J, Zhang K, and Chen S:Grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway. Cancer Prevention Research 1, 554-561, 2008.
84. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, et al.: Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clinical Cancer Research 10, 2190-2202, 2004.
85. Chen F, Wang T, Wu YF, Gu Y, Xu XL, et al.: Honokiol: a potent chemotherapy candidate for human colorectal carcinoma. World J Gastroenterol 10, 3459-3463, 2004. (Pubitemid 39549546)
86. Jiang C, Agarwal R, and Lü J: Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochemical and Biophysical Research Communications 276, 371-378, 2000.
87. Trompezinski S, Bonneville M, Pernet I, Denis A, Schmitt D, et al.: Gingko biloba extract reduces VEGF and CXCL-8/IL-8 levels in keratinocytes with cumulative effect with epigallocatechin-3-gallate. Archives of Dermatological Research 302, 183-189, 2010.
88. Lee KY, You HJ, Jeong HG, Kang JS, Kim HM, et al.: Polysaccharide isolated from Poria cocos sclerotium induces NF-κB/Rel activation and iNOS expression through the activation of p38 kinase in murine macrophages. International Immunopharmacology 4, 1029-1038, 2004. (Pubitemid 38844177)
89. Sato K, Mochizuki M, Saiki I, Yoo YC, Samukawa K, et al.: Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biological & Pharmaceutical Bulletin 17, 635, 1994.
90. Kim JM, Kim K, Lee Y, Cho C, Yoo H, et al.: Anti-angiogenic effects of water extract of a formula consisting of Pulsatilla koreana, Panax ginseng and Glyc yrrhiza uralensis. Zhong Xi Yi Jie He Xue Bao 9, 1005-1013, 2011.
91. Kang W, Lee S, Jeon E, Yun YR, Kim KH, et al.:. Emerging role of vitamin D in colorectal cancer. World Journal of Gastrointestinal Oncology 3), 123, 2011.
92. Kimura Y, Kido T, Takaku T, Sumiyoshi M, and Baba K: Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. Cancer Science 95, 758-764, 2004. (Pubitemid 39335097)
93. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, et al.: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Molecular Cancer Therapeutics 7, 1789, 2008.
94. Liu LZ, Fang J, Zhou Q, Hu X, Shi X, et al.: Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Molecular Pharmacology 68, 635-643, 2005. (Pubitemid 41206017)
95. Thippeswamy G, Sheela M, and Salimath BP: Octacosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-κB and its DNA binding activity. European Journal of Pharmacology 588, 141-150, 2008.
96. Shishodia S, Harikumar KB, Dass S, Ramawat KG, and Aggarwal BB: The guggul for chronic diseases: ancient medicine, modern targets. Anticancer Research 28(6A), 3647-3664, 2008.
97. Chi T. Sea Cucumber Extract and Extracts of Cyperus and Curcuma: A novel combination of natural supplements for cancer therapy. Int J Integ Oncol 2, 7-15, 2008.
98. Tang J, Feng Y, Tsao S, Wang N, Curtain R, et al.: Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. Journal of Ethnopharmacology 126, 5-17, 2009.
99. Gong YQ, Fan Y, Wu DZ, Yang H, Hu ZB, et al.: In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. European Journal of Cancer 40, 1554-1565, 2004. (Pubitemid 38757744)